The topic of biologic therapy for IBD has been selected for this Focus ... or biologic agents once corticosteroids are indicated, to induce clinical remissions. Factors such as extensive disease ...

More clinical trials need to be carried out in order to find new agents as routine treatments for IBD patients. Considering the efficacy, indication and side effects of biological agents ...

The overlap of biologics during medication switches is common in routine care of patients with IBD and isn’t linked to a higher risk for infection than nonoverlapping switches of biologics.

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Respondr TNF is the first test to predict an inflammatory bowel disease (IBD ... adalimumab and their biosimilars prior to therapy administration. Biologic medications that suppress the body's ...

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...

Analysts have suggested that TL1A inhibitors could have blockbuster sales potential as second-line therapy for IBD refractory to first-line TNF biologics ... for other I&I indications.